ZVRAZevra Therapeutics, Inc.
$11.00+7.9% 1Y
$11.00
$8.1052 weeks$14.74
ZVRA in its own filings
ZVRA's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
305
Events found in the filings · across 865 filings · the record starts in 2015
- Hard flags
- 4
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Jan 15, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Restatement admitted (non-reliance)past_3y
- 2024-03-28
- Change in certifying accountant2 occurrences
- 2022-06-17
- Late periodic reporthistorical
- 2017-05-16
- Delisting notice / listing-rule failure8 occurrences
- 2020-05-20
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2020-08-11
- SEC comment-letter activity37 occurrences
- 2025-04-17
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Zevra Reports Second Quarter 2026 Financial Results and Corporate Update.Earnings release · press release
- May 6, 2026Zevra Reports First Quarter 2026 Financial Results and Corporate Update.Earnings release · press release
- Mar 16, 2026On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned …Material agreement entered · Form 8-K
- Mar 9, 2026On March 4, 2026, the Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026.Earnings release · Form 8-K
- Dec 17, 2025On December 11, 2025, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal accounting officer, as interim principal financial officer, effective as of January 1, 2026.Director or officer change · Form 8-K
- Dec 2, 2025On November 26, 2025, Wendy Dixon notified the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) that she was resigning from the Board and each committee of the Board on which she served, subject to the Board’s acceptance.Director or officer change · Form 8-K
- Nov 20, 2025On November 20, 2025, R. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign from his position, effective December 31, 2025 (the “Separation Date”), in order to pursue other professional …Director or officer change · Form 8-K
- Nov 5, 2025Zevra Reports Third Quarter 2025 Financial Results and Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…